ArsenalBio's Co-Founder & CEO Ken Drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features

He describes the ArsenalBio's "CITE" platform, which allows it to make heterogenous cells by inserting modifications all in the same place. Plus, writing in logic gating, harnessing shRNA, and more. The company recently raised a $325M series C.